Alexion Pharmaceuticals will buy Synageva BioPharma in an $8.4 billion deal for a rare disease-treatment maker that lost nearly $60 million in the first quarter and has no products on the market.
Alexion Pharmaceuticals will pay a huge premium to buy Synageva BioPharma in an $8.4 billion deal for a rare disease treatment maker that lost nearly $60 million in the first quarter and has no products on the market.
Alexion made the deal, announced Wednesday morning, more for what Synageva can offer rather than what it already provides. That includes access to a potential blockbuster drug and stronger footing in lucrative field where drugmakers can command top dollar for treatments without facing fierce negotiations from insurers and other payers.